Harrow, Inc. (HROW) Launches HarrowRx E-Prescribing Platform

What happened

Harrow launched HarrowRx, an e-prescribing and patient-access platform for its branded eye-care medicines, including VEVYE. The platform is available to eye-care providers through connected electronic medical record systems, which are software used to manage patient and clinical information.

Confirmed

Global impact / market context

The platform creates another route for providers to prescribe Harrow’s branded medicines and help patients access them. If providers use it, that could support prescriptions and sales; however, the supplied article gives no adoption, prescription, patient-access, or revenue figures to show a commercial effect.

Analyst inference

The article says HarrowRx extends an existing partnership with PHIL and follows Harrow’s direct-to-patient program. Those channels provide context for the launch, but no details quantify their contribution or show whether the new provider platform will increase sales or reduce access costs.

Analyst inference

What to watch

1. Watch for disclosed provider adoption or use through connected electronic medical record systems, which would indicate whether the platform is reaching the clinicians it is designed to serve. Analyst inference
2. Look for prescription, patient-access, or revenue figures tied to HarrowRx, especially for VEVYE; these would help establish whether availability is translating into measurable commercial results. Analyst inference
3. Any company update on the platform’s portfolio coverage or its relationship with PHIL could clarify how HarrowRx fits with Harrow’s existing provider and direct-to-patient channels. Analyst inference

Evidence

• Original source link unavailable